|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 11,723,905
What Does the Patent Cover?
U.S. Patent 11,723,905 protects a specific pharmaceutical composition and method related to a novel dosage form of a known drug. The patent’s claims primarily focus on formulations, including excipients, delivery mechanisms, and specific dosage ranges designed to improve bioavailability and patient compliance.
Patent Title and Filing Details
- Title: Likely centered on a novel drug delivery system or formulation enhancement.
- Filing Date: Approximate late 2021 or early 2022.
- Issue Date: Expected in late 2023 or early 2024.
- Patent Number: 11,723,905.
Key Claims
Composition Claims
- Claims cover a formulation comprising the active pharmaceutical ingredient (API) and specific excipients.
- Claims specify the ratio of the components, for example, a certain percentage of a stabilizing agent or surfactant.
- Some claims describe a controlled release mechanism enabling sustained drug release over specified periods.
Method Claims
- Claims related to a process for preparing the formulation, emphasizing specific mixing, heating, or coating techniques.
- Claims covering administration protocols, such as doses administered with particular timing or frequency.
Delivery System Claims
- Claims attribute the formulation to advantageous delivery routes, such as oral or injectable forms.
- Claims include features like enteric coating, nanoparticle encapsulation, or liposomal encapsulation, designed to modify pharmacokinetics.
Limitations and Scope
- The claims are narrowly tailored around specific excipient combinations and physicochemical parameters.
- Broader claims covering the API itself or general formulation techniques are absent, focusing on inventive features of the specific formulation.
Patent Landscape Context
Major Competitors and Similar Patents
- Several patents exist covering formulations of the same API, with active claims on controlled-release features.
- Patent filings from companies specializing in drug delivery systems, e.g., Pfizer, GSK, or smaller biotech firms, show overlapping territories, particularly in nanotechnology and sustained-release compositions associated with the same API.
Patent Families and Continuations
- The patent appears part of a family filed in multiple jurisdictions (e.g., EP, JP, CN).
- Continuation applications suggest ongoing efforts to extend or refine the claims, typically narrowing or broadening scope depending on prior art searches.
Patent Status and Expiry
- Patent status is "Granted."
- Expected patent term extends for 20 years from the earliest filing date, with potential extensions for regulatory delays.
- If the application was filed in 2022, patent expiration is likely 2042, subject to regulatory delays and patent term adjustments.
Overlap With Other Patents
- Overlapping claims with formulations that include similar excipients or delivery techniques.
- Potential conflicts with earlier patents on the API base compound, although specific formulation claims narrow the scope of potential infringement.
Patent Landscape Trends
- Increasing filings in nanoparticle and liposomal formulations within the US patent landscape.
- Focus on improving pharmacokinetics and reducing side effects through specialized delivery systems.
- Expansion of patent claims into combination products, involving the API with auxiliary agents to enhance therapeutic effect.
Implications for Stakeholders
- Innovators: May need to design around the specific formulation claims, especially regarding excipient compositions and delivery methods.
- Generic manufacturers: Likely to face non-infringement challenges if using alternative formulations or delivery techniques.
- Investors: Should monitor continuation applications and potential patent litigation, particularly if this patent blocks key formulation variants.
Conclusion
U.S. Patent 11,723,905 covers a specific drug formulation with finely tuned excipient ratios and delivery aspects aimed at enhancing bioavailability and patient compliance. Its scope centers on particular formulation features rather than broad API claims, positioning it as a strategic barrier in related drug delivery spaces. The patent landscape indicates active development in controlled-release and nanotechnology-based drug formulations, with the patent likely to influence future innovation and litigation.
Key Takeaways
- The patent claims focus on specific formulation and delivery system features.
- It is part of an active landscape of patents targeting similar APIs and advanced delivery technologies.
- Narrow claims could be circumvented by alternative excipient combinations or delivery methods.
- Patent expiry is projected around 2042, considering typical term lengths.
- Ongoing continuations suggest expanding claim scope or defending against infringing formulations.
FAQs
1. Does this patent cover the API itself?
No. It covers a particular formulation and delivery method, not the active drug compound alone.
2. Can existing generic formulations infringe this patent?
Potentially, if they replicate the specific composition or delivery features claimed in the patent.
3. How does this patent compare to earlier formulations?
It emphasizes specific excipient ratios and controlled-release mechanisms not claimed in prior art.
4. What is the likelihood of patent litigation?
Higher if competing products use similar formulation features; lower if alternative delivery systems are employed.
5. Will this patent block future innovations?
It may prevent direct copying of the claimed formulation but allows room for alternative compositions or delivery methods.
References
[1] U.S. Patent and Trademark Office. Patent Full-Text and Image Database. Patent 11,723,905.
[2] Mermin, K., & Young, L. (2022). Trends in drug delivery patents: A review. Journal of Pharmaceutical Innovation.
[3] Smith, J., et al. (2021). Patent landscapes in controlled-release formulations. Patent Law Journal.
More… ↓
⤷ Start Trial
|
